Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Everolimus in Advanced HCC
NCT00775073Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2008
- Primary completion
- Jan 2011
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- everolimus
- Conditions
- hepatocellular carcinoma (HCC)
01
Overview
Phase 2, open-label, single-arm trial of everolimus in hepatocellular carcinoma (HCC). Primary endpoint: Time to Progression at 48 weeks. Started Oct 2008; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Treatment
Bevacizumab + Everolimus
03
Endpoints
Primary
Time to Progression
Secondary
Overall Survival
Beyond the preview
Go deeper on NCT00775073.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00775073.